BeOne Medicines (ONC) Net Cash Flow (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Net Cash Flow data on file, last reported at $224.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 301.06% year-over-year to $224.5 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 995.0% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 485.62% from the prior year.
• Net Cash Flow for Q1 2026 stood at $224.5 million, down from $475.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for ONC reached as high as $1.3 billion in Q3 2025 and fell as low as -$390.0 million in Q4 2022.
• Historically, Net Cash Flow has averaged $30.6 million across 5 years, with a median of -$37.4 million in 2022.
• Across the five-year window, Net Cash Flow tumbled 815.09% in 2023 and soared 2172.2% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$390.0 million in 2022, then surged by 116.11% to $62.8 million in 2023, then sank by 136.56% to -$23.0 million in 2024, then surged by 2172.2% to $475.9 million in 2025, then tumbled by 52.84% to $224.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $224.5 million in Q1 2026, $475.9 million in Q4 2025, and $1.3 billion in Q3 2025.